Insmed reports Q4 EPS ($1.28), consensus ($1.15)

Reports Q4 revenue $83.7M, consensus $82.76M. “Insmed continued to deliver strong performance in 2023, demonstrating commercial success evidenced by ARIKAYCE revenues that exceeded the upper end of our 2023 sales guidance range,” said CEO Will Lewis. “The positive ARISE data announced in September 2023, followed by encouraging blinded TPIP data shortly thereafter, marked the beginning of a transformative period of clinical catalysts for the Company. This series of meaningful data readouts from our mid- to late-stage pipeline is expected to continue uninterrupted in the months ahead, with topline results from the PH-ILD and ASPEN trials expected in quick succession in the second quarter. We believe these near-term data readouts have the potential to fundamentally change the trajectory for our company and the patients we serve.”